Primary and Secondary Effects of Mass Antibiotic Distributions for Trachoma
大规模抗生素分发对沙眼的主要和次要影响
基本信息
- 批准号:8719112
- 负责人:
- 金额:$ 22.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvocateAffectAftercareAntibiotic TherapyAntibioticsAzithromycinBiological AssayBlindnessChildChild MortalityChildhoodChlamydiaChlamydia trachomatisClinical TrialsCommunitiesDNADataDiarrheaDiseaseDoseEthiopiaEye diseasesFoundationsFrequenciesFutureGoalsGrowthHeightIndividualInfectionInternationalIvermectinK-Series Research Career ProgramsLung diseasesMalariaMeasuresMedicineMentorshipMetabolismMethodsMorbidity - disease rateNucleic AcidsNutrientNutritional statusOnchocerciasisOphthalmia NeonatorumOphthalmologyOralPopulationPopulation AnalysisPreschool ChildProphylactic treatmentRandomizedRecording of previous eventsResearchResearch InfrastructureResearch PersonnelRibosomal RNASafetySamplingSampling StudiesTestingTrachomaTrainingTranslatingTropical DiseaseVitamin AWeightWorkXerophthalmiaabsorptionabstractingagedarmbaseblindcareerdesignexperiencegastrointestinalimprovedindexinginstrumentmanmeetingsmembermortalityneglectnutritionprogramspublic health relevancetreatment effect
项目摘要
Abstract
I have two objectives in seeking a K23 career development award: 1. to improve our understanding of the
effects of mass antibiotic distributions for trachoma by conducting an in depth analysis of populations in which
trachoma has ostensibly been eliminated and by assessing the positive secondary effects of mass antibiotic
treatments on childhood morbidity and mortality; 2. to develop my career as an independent investigator
through didactics, mentorship and hands-on research experience in the developing world. I will benefit from the
infrastructure of two clinical trials: TANA (Trachoma Amelioration in Northern Amhara, U10 EY016214) and
PRET (Partnership for the Rapid Elimination of Trachoma, Gates Foundation, #48027). The WHO launched
the GET 2020 (Global Elimination of Trachoma by the year 2020) program to eliminate blinding trachoma,
however, the goals have not been met, particularly in hyperendemic communities. Mass treatments have been
used in several elimination campaigns and have been found to have unintended secondary effects.
I have the following specific aims:
SA1: To determine if C. trachomatis infection can be eliminated using rRNA-based nucleic acid amplification
compared to DNA-based testing.
SA2a: To determine if azithromycin treatments reduce mortality in 1-5 year olds from diarrhea, respiratory
disease and malaria.
SA2b: To determine if azithromycin treatments effect increases in height, weight, and arm circumference.
My goal is to determine if complete elimination is attainable in hyperendemic communities and then to translate
these research findings quickly into practice within trachoma programs in general and within the WHO GET
2020 program in particular. Growth indices are a common method for determining the efficacy of mass
treatment; developing and testing an instrument for measuring growth and nutrition will provide an important
bridge to future studies on integration of trachoma with other neglected tropical diseases (NTD).
摘要
我申请K23职业发展奖有两个目的:1.加深我们对
通过对以下人群进行深入分析,了解大规模抗生素分布对沙眼的影响
沙眼表面上已经被消除了,通过评估大量抗生素的积极辅助作用
儿童发病率和死亡率的治疗;2.发展我作为独立调查员的职业生涯
通过教学、指导和在发展中国家的实践研究经验。我将受益于
两项临床试验的基础设施:TANA(北阿姆哈拉沙眼改善,U10 EY016214)和
PRET(快速根除沙眼伙伴关系,盖茨基金会,48027号)。世界卫生组织发起
GET 2020(到2020年全球消除沙眼)计划,以消除致盲沙眼,
然而,这些目标尚未实现,特别是在高度流行的社区。大规模的治疗已经被
在几次消灭运动中使用,并被发现有意想不到的次要影响。
我有以下具体目标:
SA1:确定是否可以通过基于rRNA的核酸扩增来消除沙眼衣原体感染
与基于DNA的检测相比。
SA2a:确定阿奇霉素治疗是否能降低1-5岁儿童腹泻、呼吸道疾病的死亡率
疾病和疟疾。
SA2B:确定阿奇霉素治疗是否能增加身高、体重和臂围。
我的目标是确定在高度流行的社区中是否可以实现完全消除,然后将
这些研究成果在一般沙眼项目和世界卫生组织范围内迅速付诸实践
特别是2020年计划。生长指数是确定质量疗效的常用方法。
治疗;开发和测试一种测量生长和营养的仪器将提供重要的
为沙眼与其他被忽视的热带病(NTD)整合的未来研究铺平了道路。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.
- DOI:10.1371/journal.pntd.0002303
- 发表时间:2013
- 期刊:
- 影响因子:3.8
- 作者:Liu F;Porco TC;Ray KJ;Bailey RL;Mkocha H;Muñoz B;Quinn TC;Lietman TM;West SK
- 通讯作者:West SK
The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial.
- DOI:10.1016/j.epidem.2013.12.001
- 发表时间:2014-03
- 期刊:
- 影响因子:3.8
- 作者:Liu, Fengchen;Porco, Travis C.;Mkocha, Harran A.;Munoz, Beatriz;Ray, Kathryn J.;Bailey, Robin L.;Lietman, Thomas M.;West, Sheila K.
- 通讯作者:West, Sheila K.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce D. Gaynor其他文献
Bruce D. Gaynor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce D. Gaynor', 18)}}的其他基金
Primary and Secondary Effects of Mass Antibiotic Distributions for Trachoma
大规模抗生素分发对沙眼的主要和次要影响
- 批准号:
7770211 - 财政年份:2010
- 资助金额:
$ 22.58万 - 项目类别:
Primary and Secondary Effects of Mass Antibiotic Distributions for Trachoma
大规模抗生素分发对沙眼的主要和次要影响
- 批准号:
8129513 - 财政年份:2010
- 资助金额:
$ 22.58万 - 项目类别:
Primary and Secondary Effects of Mass Antibiotic Distributions for Trachoma
大规模抗生素分发对沙眼的主要和次要影响
- 批准号:
8323422 - 财政年份:2010
- 资助金额:
$ 22.58万 - 项目类别:
Primary and Secondary Effects of Mass Antibiotic Distributions for Trachoma
大规模抗生素分发对沙眼的主要和次要影响
- 批准号:
8536298 - 财政年份:2010
- 资助金额:
$ 22.58万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 22.58万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 22.58万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 22.58万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 22.58万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 22.58万 - 项目类别: